Open Clinical Trials
Principal Investigator: Michael E. Bromberg, MD, PhD
Primary Contact: Gibson T. George
Title: A two-arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE®(bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab maintenance in Patients with Relapsed Follicular Lymphoma. Millenium.
Diagnoses: Relapsed follicular lymphoma or marginal zone lymphoma
Study Inclusion Criteria:
- Male or female 18 years or older
- Diagnosis of follicular lymphoma or marginal zone lymphoma
- Recurrence of symptoms following prior treatment
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11913.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #11913.
Principal Investigator: Michael E. Bromberg, MD, PhD
Primary Contact: Gibson T. George
Title: A Safety And Efficacy Trial Evaluating The Use Of Apixaban In The Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism.
Diagnoses: Deep Vein Thrombosis or Pulmonary Embolism
Study Inclusion Criteria:
- Male or female 18 years or older
- Patients presenting with new onset of DVT and PE
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12262.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12262.
Principal Investigator: Michael E. Bromberg, MD, PhD
Primary Contact: Gibson T. George
Title: A Prospective, Non-Interventional Multicenter Registry in Iron Overloaded Lower-Risk Myelodysplastic Patients. Novartis.
Diagnoses: Myelodysplastic syndromes
Study Inclusion Criteria:
- Male or female 18 years or older
- Diagnoses of myelodysplastic syndromes requiring blood transfusion
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11658.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #11658.
Principal Investigator: Michael E. Bromberg, MD, PhD
Primary Contact: Gibson T. George
Title: A Worldwide Observational Registry collecting Longitudinal Data on the management of Chronic Myelogenous Leukemia (CML) patients in routine practice. Novartis.
Diagnoses: Chronic myelogenous leukemia (registry)
Study Inclusion Criteria:
- Male or female 18 years or older
- Diagnosis of chronic myelogenous leukemia within 6 months
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11639.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #11639.
Principal Investigator: Michael E. Bromberg, MD, PhD
Primary Contact: Gibson T. George
Title: Bone marker directed dosing of ZOMETA® (zoledronic acid) for the prevention of skeletal complications in patients with advanced multiple myeloma. Novartis.
Diagnoses: Multiple myeloma
Study Inclusion Criteria:
- Male or female 18 years or older
- Diagnosis of multiple myeloma
- Started on IV biophosphonate (Bone Medication) between 1-2 years ago
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11698.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #11698.
Principal Investigator: Michael E. Bromberg, MD, PhD
Primary Contact: Thomas Parsons
Title: A randomized, double blind, placebo controlled study evaluating the efficacy & safety of romiplostim treatment of thrombocytopenia in subjects with low or intermediate-1 risk Myelodysplastic Syndrome (MDS). Amgen.
Diagnoses: Low or intermediate risk myelodysplastic syndrome
Study Inclusion Criteria:
This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11782.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #11782.
Principal Investigator: Curtis Miyamoto, MD
Primary Contact: Thomas Parsons
Title: Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. EUSA.
Diagnoses: Mucositis
Study Inclusion Criteria:
- Male or female 18 years or older
- Diagnosis of head and neck cancer
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12390.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12390.
For more information about these or any other clinical trials available at the Temple Cancer Center, please call the Research Office at 215-707-9433.
TOP